Literature DB >> 10844550

The neurofibromatosis type 1 (Nf1) tumor suppressor is a modifier of carcinogen-induced pigmentation and papilloma formation in C57BL/6 mice.

R P Atit1, K Mitchell, L Nguyen, D Warshawsky, N Ratner.   

Abstract

There is increasing evidence implicating the human NF1 gene in epithelial carcinogenesis. To test if NF1 can play a part in skin tumor formation, we analyzed effects of the skin cancer initiator dimethylbenz-anthracene and/or the tumor promoter 12-O-tetradecanoyl-13-acetylphorbol on mice heterozygous for null mutations in Nf1 (Nf1+/-). Mice were on the C57BL/6 background, noted for resistance to chemical carcinogens. Nf1+/- mice (18 of 24) developed papillomas after treatment with dimethylbenzanthracene and 12-O-tetradecanoyl-13-acetylphorbol; papillomas did not develop in wild-type C57BL/6 mice nor Nf1+/- mice treated with 12-O-tetradecanoyl-13-acetylphorbol alone. All papillomas analyzed (six of six) had mutations in codon 61 of H-ras, demonstrating strong cooperation between the Nf1 GTPase activating protein for Ras, neurofibromin, and Ras-GTP. After exposure to 12-O-tetradecanoyl-13-acetylphorbol, Nf1+/- keratinocytes showed significant, sustained, increases in proliferation, implicating Nf1 in phorbol ester responsive pathways. Thus, Nf1 levels regulate the response of keratinocytes to 12-O-tetradecanoyl-13-acetylphorbol. Nf1+/- mice also showed a 2-fold increase in the development of pigmented skin patches stimulated by dimethylbenzanthracene; patches were characterized by hair follicles in anagen phase, implicating keratinocytes in the aberrant hyperpigmentation. Our results show that mutation in the Nf1 gene causes abnormal keratinocyte proliferation that can be revealed by environmental assaults such as carcinogen exposure. The data support a plausible role for NF1 mutation in human epithelial carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10844550      PMCID: PMC2862652          DOI: 10.1046/j.1523-1747.2000.00994.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  53 in total

1.  Ornithine decarboxylase overexpression is a sufficient condition for tumor promotion in mouse skin.

Authors:  T G O'Brien; L C Megosh; G Gilliard; A P Soler
Journal:  Cancer Res       Date:  1997-07-01       Impact factor: 12.701

2.  Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients.

Authors:  T N Basu; D H Gutmann; J A Fletcher; T W Glover; F S Collins; J Downward
Journal:  Nature       Date:  1992-04-23       Impact factor: 49.962

Review 3.  Hair follicles, stem cells, and skin cancer.

Authors:  S J Miller; T T Sun; R M Lavker
Journal:  J Invest Dermatol       Date:  1993-03       Impact factor: 8.551

4.  v-Ha-ras transgene abrogates the initiation step in mouse skin tumorigenesis: effects of phorbol esters and retinoic acid.

Authors:  A Leder; A Kuo; R D Cardiff; E Sinn; P Leder
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

5.  Urinary bladder transitional cell carcinogenesis is associated with down-regulation of NF1 tumor suppressor gene in vivo and in vitro.

Authors:  V Aaltonen; P J Boström; K O Söderström; O Hirvonen; J Tuukkanen; M Nurmi; M Laato; J Peltonen
Journal:  Am J Pathol       Date:  1999-03       Impact factor: 4.307

6.  NF1 inactivation cooperates with N-ras in in vivo lymphogenesis activating Erk by a mechanism independent of its Ras-GTPase accelerating activity.

Authors:  R Mangues; T Corral; S Lu; W F Symmans; L Liu; A Pellicer
Journal:  Oncogene       Date:  1998-10-01       Impact factor: 9.867

7.  Murine susceptibility to two-stage skin carcinogenesis is influenced by the agent used for promotion.

Authors:  J J Reiners; S Nesnow; T J Slaga
Journal:  Carcinogenesis       Date:  1984-03       Impact factor: 4.944

8.  Sensitivity of the skin of different mouse strains to the promoting effect of 12-0-tetradecanoyl-phorbol-13-acetate.

Authors:  I Chouroulinkov; C Lasne; D Phillips; P Grover
Journal:  Bull Cancer       Date:  1988       Impact factor: 1.276

9.  Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues.

Authors:  C I Brannan; A S Perkins; K S Vogel; N Ratner; M L Nordlund; S W Reid; A M Buchberg; N A Jenkins; L F Parada; N G Copeland
Journal:  Genes Dev       Date:  1994-05-01       Impact factor: 11.361

10.  Neurofibromin can inhibit Ras-dependent growth by a mechanism independent of its GTPase-accelerating function.

Authors:  M R Johnson; J E DeClue; S Felzmann; W C Vass; G Xu; R White; D R Lowy
Journal:  Mol Cell Biol       Date:  1994-01       Impact factor: 4.272

View more
  12 in total

Review 1.  Plexiform neurofibroma genesis: questions of Nf1 gene dose and hyperactive mast cells.

Authors:  Karl Staser; Feng-Chun Yang; David W Clapp
Journal:  Curr Opin Hematol       Date:  2010-07       Impact factor: 3.284

2.  Characterization of early communicative behavior in mouse models of neurofibromatosis type 1.

Authors:  Susan E Maloney; Krystal C Chandler; Corina Anastasaki; Michael A Rieger; David H Gutmann; Joseph D Dougherty
Journal:  Autism Res       Date:  2017-08-26       Impact factor: 5.216

Review 3.  Heterozygous Tumor Suppressor Microenvironment in Cancer Development.

Authors:  Jean-Philippe Brosseau; Lu Q Le
Journal:  Trends Cancer       Date:  2019-08-15

4.  Hyperactivation of p21ras and PI3K cooperate to alter murine and human neurofibromatosis type 1-haploinsufficient osteoclast functions.

Authors:  Feng-Chun Yang; Shi Chen; Alexander G Robling; Xijie Yu; Todd D Nebesio; Jincheng Yan; Trent Morgan; Xiaohong Li; Jin Yuan; Janet Hock; David A Ingram; D Wade Clapp
Journal:  J Clin Invest       Date:  2006-10-19       Impact factor: 14.808

Review 5.  Mast cells and the neurofibroma microenvironment.

Authors:  Karl Staser; Feng-Chun Yang; D Wade Clapp
Journal:  Blood       Date:  2010-03-16       Impact factor: 22.113

6.  Multiple increased osteoclast functions in individuals with neurofibromatosis type 1.

Authors:  David A Stevenson; Jincheng Yan; Yongzheng He; Huijie Li; Yaling Liu; Qi Zhang; Yongmin Jing; Zhiping Guo; Wei Zhang; Dalong Yang; Xiaohua Wu; Heather Hanson; Xiaohong Li; Karl Staser; David H Viskochil; John C Carey; Shi Chen; Lucy Miller; Kent Roberson; Laurie Moyer-Mileur; Menggang Yu; Elisabeth L Schwarz; Marzia Pasquali; Feng-Chun Yang
Journal:  Am J Med Genet A       Date:  2011-04-04       Impact factor: 2.802

7.  Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.

Authors:  Wei Zhang; Steven D Rhodes; Liming Zhao; Yongzheng He; Yingze Zhang; Yong Shen; Dalong Yang; Xiaohua Wu; Xiaohong Li; Xianlin Yang; Su-Jung Park; Shi Chen; Charles Turner; Feng-Chun Yang
Journal:  Bone       Date:  2011-03-23       Impact factor: 4.398

8.  Hyperactive Ras/MAPK signaling is critical for tibial nonunion fracture in neurofibromin-deficient mice.

Authors:  Richa Sharma; Xiaohua Wu; Steven D Rhodes; Shi Chen; Yongzheng He; Jin Yuan; Jiliang Li; Xianlin Yang; Xiaohong Li; Li Jiang; Edward T Kim; David A Stevenson; David Viskochil; Mingjiang Xu; Feng-Chun Yang
Journal:  Hum Mol Genet       Date:  2013-07-17       Impact factor: 6.150

9.  Mouse models of neurofibromatosis 1 and 2.

Authors:  David H Gutmann; Marco Giovannini
Journal:  Neoplasia       Date:  2002 Jul-Aug       Impact factor: 5.715

Review 10.  How does the Schwann cell lineage form tumors in NF1?

Authors:  Steven L Carroll; Nancy Ratner
Journal:  Glia       Date:  2008-11-01       Impact factor: 8.073

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.